QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:ACRS

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

$17.48
+0.66 (+3.92%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$16.70
$17.68
50-Day Range
$14.60
$18.37
52-Week Range
$9.84
$18.96
Volume
1.02 million shs
Average Volume
380,759 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.67

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.0% Upside
$28.67 Price Target
Short Interest
Healthy
5.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Aclaris Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$460,650 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.39) to ($1.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

500th out of 1,055 stocks

Pharmaceutical Preparations Industry

243rd out of 519 stocks


ACRS stock logo

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

Aclaris Therapeutics (NASDAQ:ACRS) Trading Down 2.9%
ACRS Aclaris Therapeutics, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update
Aclaris Therapeutics Provides 2023 Outlook
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
SVB Securities Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Announces Key Leadership Transitions
Aclaris Therapeutics Looks Promising on the Charts
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.67
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+64.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-90,860,000.00
Net Margins
-349.26%
Pretax Margin
-349.26%

Debt

Sales & Book Value

Annual Sales
$6.76 million
Book Value
$3.22 per share

Miscellaneous

Free Float
62,215,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
0.53

Key Executives

  • Dr. Neal S. Walker D.O. (Age 53)
    Co-Founder, CEO & Director
    Comp: $965.59k
  • Dr. Joseph Monahan Ph.D. (Age 67)
    Chief Scientific Officer
    Comp: $515.3k
  • Dr. Douglas J. Manion Frcp(C) (Age 62)
    M.D., Pres & COO
  • Mr. Robert A. Doody Jr.
    VP of Investor Relations
  • Mr. Matthew Rothman J.D.
    Gen. Counsel & Corp. Sec.
  • Dr. Jon Jacobsen Ph.D.
    Sr. VP of Chemistry
  • Dr. Paul S. Changelian Ph.D.
    Sr. VP of Biology
  • Mr. James Loerop (Age 58)
    Chief Bus. Officer
  • Dr. Ian Anderson Ph.D.
    Exec. VP of Translational R&D
  • Dr. Gail Cawkwell M.D. (Age 61)
    Ph.D., Chief Medical Officer













ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 1-year price targets for Aclaris Therapeutics' stock. Their ACRS share price forecasts range from $25.00 to $32.00. On average, they predict the company's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 64.0% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2023?

Aclaris Therapeutics' stock was trading at $15.75 at the beginning of the year. Since then, ACRS shares have increased by 11.0% and is now trading at $17.48.
View the best growth stocks for 2023 here
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,840,000 shares, a decline of 5.0% from the December 31st total of 2,990,000 shares. Based on an average trading volume of 349,100 shares, the days-to-cover ratio is currently 8.1 days. Currently, 5.5% of the shares of the stock are short sold.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings data on Tuesday, November, 8th. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.09. The biotechnology company had revenue of $19.02 million for the quarter, compared to analyst estimates of $1.61 million. Aclaris Therapeutics had a negative net margin of 349.26% and a negative trailing twelve-month return on equity of 39.41%.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%) and Strs Ohio (0.05%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $17.48.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $1.17 billion and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 1/27/2023 by MarketBeat.com Staff